Abecma (Idecabtagene Vicleucel)
CAR-T cell therapy for relapsed or refractory multiple myeloma
Quick Facts About Abecma
Key Takeaways About Abecma
- Personalized therapy: Abecma is made from your own white blood cells, genetically modified to fight your specific cancer
- One-time infusion: Unlike ongoing treatments, Abecma is given as a single intravenous infusion at a specialized center
- Serious side effects possible: Cytokine release syndrome (CRS) and neurotoxicity (ICANS) are potentially life-threatening risks requiring close monitoring
- Stay near the hospital: Patients must remain near the treatment center for at least two weeks after infusion for safety monitoring
- Last-line treatment: Abecma is used when previous myeloma treatments have failed, offering hope for patients with limited options
What Is Abecma and What Is It Used For?
Abecma (idecabtagene vicleucel) is a type of cancer immunotherapy called CAR-T cell therapy. It is used to treat adults with multiple myeloma, a cancer of the bone marrow, when previous treatments have not worked or the cancer has returned after treatment.
Abecma represents a fundamentally different approach to cancer treatment. Rather than using traditional chemotherapy drugs or radiation to kill cancer cells, Abecma harnesses the power of the patient's own immune system. The treatment involves collecting white blood cells called T cells from the patient's blood, genetically engineering them in a laboratory to recognize and attack cancer cells, and then infusing them back into the patient's body.
The active substance in Abecma is idecabtagene vicleucel, sometimes abbreviated as ide-cel. Each dose is uniquely manufactured for an individual patient using their own T cells. These modified cells are equipped with a chimeric antigen receptor (CAR) that specifically targets a protein called B-cell maturation antigen (BCMA), which is found on the surface of myeloma cancer cells.
Multiple myeloma is a type of blood cancer that develops in the bone marrow from plasma cells, a type of white blood cell normally responsible for producing antibodies. When these plasma cells become cancerous, they multiply uncontrollably and can crowd out healthy blood cells, weaken bones, and damage organs. According to the World Health Organization, multiple myeloma accounts for approximately 10% of all hematological malignancies worldwide.
How Abecma Works
The mechanism of action of Abecma involves several key steps. First, white blood cells (T cells) are isolated from the patient's blood through a process called leukapheresis. These T cells are then sent to a specialized manufacturing facility where they are genetically modified to express a chimeric antigen receptor (CAR) on their surface. This receptor is designed to recognize and bind to BCMA protein on myeloma cells.
Once the modified CAR-T cells are infused back into the patient's bloodstream, they circulate throughout the body seeking out myeloma cells. When a CAR-T cell encounters a cancer cell displaying BCMA on its surface, the CAR locks onto the protein. This binding triggers the T cell to activate, multiply, and directly kill the targeted cancer cell. The CAR-T cells can continue to multiply and hunt for cancer cells over an extended period, providing ongoing immune surveillance against the disease.
Clinical trials have demonstrated that Abecma can achieve meaningful responses in patients who have exhausted other treatment options. The pivotal KarMMa trial showed an overall response rate of 73% in patients who had received at least three prior lines of therapy, with 33% achieving a complete response or better. These results led to regulatory approval by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Abecma is a highly specialized treatment that can only be prepared and administered at certified treatment centers with expertise in CAR-T cell therapy. The entire process from blood collection to infusion typically takes several weeks, during which time patients may receive bridging therapy to manage their disease.
What Should You Know Before Taking Abecma?
Before receiving Abecma, your doctor will conduct thorough assessments of your heart, lungs, blood pressure, and infection status. You must not receive Abecma if you are allergic to any of its ingredients or to the lymphodepleting chemotherapy agents used in preparation. Certain conditions and medications require special consideration.
Abecma is a powerful immunotherapy that requires careful patient selection and preparation. Your healthcare team will perform a comprehensive evaluation before deciding whether this treatment is appropriate for you. This evaluation typically includes physical examinations, blood tests, imaging studies, and assessments of your organ function. Understanding the important precautions and contraindications is essential for patient safety.
Contraindications
You must not receive Abecma if:
- You are allergic (hypersensitive) to idecabtagene vicleucel or any of the other ingredients in the formulation
- You are allergic to any component of the lymphodepleting chemotherapy that is given before Abecma to prepare your body for treatment
If you think you may be allergic to any of these substances, discuss your concerns with your doctor before proceeding with treatment planning.
Warnings and Precautions
Talk to your doctor before receiving Abecma if any of the following apply to you:
- Lung or heart problems: Pre-existing cardiopulmonary conditions may increase the risk of complications from cytokine release syndrome
- Low blood pressure: Hypotension can be worsened by CRS and may require vasopressor support
- Recent stem cell transplant: If you have had a stem cell transplant within the past four months, the risk of complications may be higher
- Graft-versus-host disease (GvHD): Signs include skin rash, nausea, vomiting, diarrhea, and blood in the stool. Active GvHD must be resolved before treatment
- Active infection: Any ongoing infection will be treated and resolved before Abecma can be given
- Worsening cancer symptoms: Signs such as fever, weakness, bone pain, or unexplained weight loss should be reported to your doctor
- Previous viral infections: History of cytomegalovirus (CMV), hepatitis B or C, or HIV infection requires special consideration
- Recent vaccination: If you have received a vaccination within the past six weeks or plan to receive one in the coming months, inform your doctor
Patients treated with Abecma and similar CAR-T cell therapies have, in rare cases, developed new cancers originating from T cells (secondary T-cell malignancies). Report any new swelling of lymph nodes, changes in skin such as new rashes or lumps, or unexplained symptoms to your doctor immediately. Your healthcare team will monitor you for this risk on an ongoing basis.
Tests and Monitoring
Before you receive Abecma, your doctor will perform a thorough medical evaluation including:
- Assessment of lung function, heart health, and blood pressure
- Screening for active infections, which must be treated before proceeding
- Evaluation of your cancer status and disease burden
- Testing for CMV, hepatitis B, hepatitis C, and HIV
- Blood tests to assess your overall organ function and blood cell counts
After receiving Abecma, your doctor will regularly monitor your blood counts, as the number of various blood cells can decrease significantly. You must stay near the treatment center for at least two weeks following infusion, and daily monitoring at the clinic is typical during at least the first week. Depending on your individual response, your doctor may recommend staying near the treatment center for a longer period.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, talk to your doctor before receiving Abecma. The effects of Abecma on unborn babies and nursing infants are not known, and it could potentially harm your developing baby or breastfeeding child.
- A pregnancy test will be performed before treatment begins. Abecma should only be given if the test confirms you are not pregnant
- If you become pregnant or suspect pregnancy after receiving Abecma, contact your doctor immediately
- Discuss family planning and contraception with your healthcare team before and after treatment
Driving and Operating Machinery
You must not drive, operate machinery, or participate in activities requiring full alertness for at least four weeks after receiving Abecma, or until your doctor confirms you have fully recovered. Abecma can cause drowsiness, confusion, and seizures. Your doctor may advise you to wait even longer depending on your individual recovery.
After receiving Abecma, you must not donate blood, organs, tissues, or cells for transplantation. This is because Abecma contains genetically modified cells that should not be transferred to another person.
Children and Adolescents
Abecma is not approved for use in children and adolescents under 18 years of age. The safety and efficacy of this treatment have not been established in the pediatric population.
How Does Abecma Interact with Other Drugs?
Abecma can interact with immunosuppressive medications such as corticosteroids, which may reduce its effectiveness if used before infusion. Live vaccines are contraindicated for six weeks before lymphodepleting chemotherapy and during the immune recovery period following Abecma treatment.
Because Abecma works by modifying and enhancing your own immune cells, medications that affect the immune system can significantly impact its effectiveness. It is critical to inform your doctor about all medications you are currently taking, have recently taken, or are planning to take, including over-the-counter medicines and supplements.
Major Interactions
| Interacting Drug/Class | Effect | Recommendation |
|---|---|---|
| Corticosteroids | May suppress CAR-T cell activity and reduce therapeutic efficacy | Avoid before infusion; may be used to manage CRS/ICANS after infusion |
| Other immunosuppressants | Can weaken the modified T cells and reduce anti-tumor response | Discontinue before Abecma; discuss timing with your doctor |
| Live vaccines | Risk of infection from live attenuated organisms due to immunosuppression | Contraindicated 6 weeks before chemotherapy and during immune recovery |
| Tocilizumab | Used therapeutically to manage cytokine release syndrome | Must be available at the treatment center before infusion begins |
Vaccination Considerations
Vaccination requires special attention when undergoing CAR-T cell therapy. The following guidelines apply:
- Live vaccines (such as MMR, varicella, oral polio, yellow fever) must not be given for at least six weeks before lymphodepleting chemotherapy, during Abecma treatment, or while your immune system is recovering
- Inactivated vaccines may not produce an adequate immune response while your immune system is suppressed. Discuss the timing of any needed vaccinations with your healthcare team
- Your doctor will advise you when it is safe to resume vaccinations based on your immune recovery
Abecma can cause prolonged low levels of immunoglobulins (antibodies), a condition known as hypogammaglobulinemia. Your doctor may recommend immunoglobulin replacement therapy to help prevent infections during this period.
What Is the Correct Dosage of Abecma?
Abecma is given as a single intravenous infusion at a dose of 260 to 500 million CAR-positive viable T cells. The process involves blood collection (leukapheresis), manufacturing, lymphodepleting chemotherapy, and then the Abecma infusion itself. The entire treatment timeline spans several weeks.
Abecma is not a conventional medication with a daily dosing schedule. Instead, it follows a carefully orchestrated treatment process that unfolds over several weeks. Each step must be completed successfully before proceeding to the next. The treatment is exclusively administered at certified healthcare centers by experienced medical professionals.
Step 1: Blood Collection (Leukapheresis)
Leukapheresis Procedure
Your doctor will collect a portion of your blood through a catheter placed in a vein. White blood cells (including T cells) are separated from your blood, and the remaining blood is returned to your body. This process typically takes 3 to 6 hours and may need to be repeated. The collected T cells are frozen and shipped to the manufacturing facility.
Step 2: Manufacturing
CAR-T Cell Production
At the manufacturing facility, your T cells are genetically modified to express the anti-BCMA chimeric antigen receptor. This manufacturing process typically takes approximately 4 weeks. During this waiting period, you may receive bridging therapy (interim treatment) to control your myeloma, as directed by your doctor.
Step 3: Lymphodepleting Chemotherapy
Pre-Treatment Chemotherapy
A few days before receiving Abecma, you will receive a short course of chemotherapy called lymphodepleting conditioning. This regimen clears existing white blood cells to make room for the CAR-T cells and creates a favorable environment for them to expand. Common agents used include cyclophosphamide and fludarabine.
Step 4: Abecma Infusion
Target Dose: 260–500 × 106 CAR-positive viable T cells
Shortly before infusion, you will receive paracetamol (acetaminophen) and an antihistamine to reduce the risk of infusion reactions and fever. Your healthcare team will verify that the patient identification on the infusion bag matches your details. Abecma is infused intravenously, and one or more infusion bags may be needed to deliver the target dose. The infusion must be completed within one hour of thawing.
Adults
The recommended dose of Abecma for adults is 260 to 500 × 106 CAR-positive viable T cells, administered as a single intravenous infusion. The exact number of cells in each dose varies because the product is individually manufactured from each patient's own cells. The entire dose may require one or more infusion bags. A leukocyte-reducing filter must not be used during infusion.
Children
Abecma is not approved for use in children and adolescents under 18 years of age. There is no established pediatric dosing.
Elderly
No specific dose adjustment is required for elderly patients. Clinical trials included patients over 65 years of age, and no clinically meaningful differences in safety or efficacy were observed compared to younger adults. However, elderly patients may have more comorbidities that require careful pre-treatment assessment.
After Infusion: Monitoring
After receiving Abecma, you must remain close to the treatment center for a minimum of two weeks. During this period:
- You may be monitored daily at the clinic for at least the first week to check for side effects and assess treatment response
- Blood tests will be performed regularly to monitor your blood cell counts and organ function
- Your doctor may extend the monitoring period based on your individual needs and clinical response
- You should report any new symptoms immediately to your healthcare team
Missed Appointments
If you miss a scheduled follow-up visit, contact your doctor or the treatment center as soon as possible to reschedule. Regular monitoring is essential for detecting and managing potential complications early.
What Are the Side Effects of Abecma?
The most serious side effects of Abecma include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), severe infections, and prolonged low blood cell counts. These typically occur within the first eight weeks after infusion. Immediate medical attention is required for fever, breathing difficulties, confusion, or signs of infection.
Like all medicines, Abecma can cause side effects, although not everyone experiences them. Because Abecma works by powerfully activating the immune system, some side effects can be severe and potentially life-threatening. Your healthcare team is specially trained to recognize and manage these complications. Understanding the possible side effects and their warning signs is crucial for your safety.
Contact your doctor or go to the emergency department immediately if you experience any of the following after receiving Abecma: high fever, chills, difficulty breathing, rapid heartbeat, low blood pressure, confusion, difficulty speaking, seizures, or severe drowsiness. These may be signs of CRS or ICANS, both of which require urgent treatment.
Serious Side Effects
The following serious side effects have been reported with Abecma. They typically occur within the first eight weeks after infusion but can also appear later:
Very Common (affects more than 1 in 10 patients)
- Cytokine release syndrome (CRS): fever, chills, breathing difficulties, dizziness, nausea, headache, rapid heartbeat, low blood pressure, or fatigue
- Infections: fever, chills, cough, shortness of breath, rapid breathing, and rapid pulse
- Anemia: feeling very tired, weak, or short of breath due to low red blood cell count
- Thrombocytopenia: unusual bleeding or bruising, including nosebleeds or bleeding from the mouth or intestines, due to low platelet count
- Neutropenia: low white blood cell count increasing infection risk
- Low energy and fatigue
- High blood pressure
- Decreased appetite
- Constipation
- Swelling in ankles, arms, legs, and face
- Joint pain
- Sleep difficulties
- Hypogammaglobulinemia: low levels of protective antibodies (immunoglobulins)
- Abnormal laboratory values: decreased calcium, sodium, magnesium, potassium, phosphate, or albumin; elevated liver enzymes or C-reactive protein
Common (affects up to 1 in 10 patients)
- Parkinsonism: tremor, weakness with loss of movement on one side of the body, slow movements, or stiffness
- Muscle pain
- Abnormal body movements or poor coordination
- Irregular or uneven heartbeat
- Fluid in the lungs
- Low blood oxygen levels, which may cause shortness of breath, confusion, or drowsiness
- Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS): serious inflammation due to immune system over-activation
Uncommon (affects up to 1 in 100 patients)
- ICANS (Immune effector cell-associated neurotoxicity syndrome): confusion, memory difficulties, difficulty speaking or slower speech, difficulty understanding speech, poor balance or coordination, disorientation, reduced alertness, excessive drowsiness, loss of consciousness, or seizures
Rare (affects up to 1 in 1,000 patients)
- Secondary T-cell malignancy: a new type of cancer beginning in white blood cells called T cells
Cytokine Release Syndrome (CRS) Explained
Cytokine release syndrome is the most common serious side effect of Abecma and occurs when the activated CAR-T cells release large amounts of inflammatory proteins called cytokines into the bloodstream. CRS typically develops within the first few days after infusion and can range from mild flu-like symptoms to a life-threatening systemic inflammatory response.
Mild CRS may present as fever and fatigue, while severe CRS can cause dangerously low blood pressure, difficulty breathing requiring oxygen support, and multi-organ dysfunction. The standard treatment for significant CRS is tocilizumab, an anti-interleukin-6 receptor antibody that blocks the inflammatory cascade. Treatment centers must have tocilizumab readily available before beginning Abecma infusion. In some cases, corticosteroids may also be used.
Managing and Reporting Side Effects
It is important to report any suspected side effects to your healthcare team promptly. Early detection and treatment of complications such as CRS and ICANS can significantly improve outcomes. Your medical team has specific protocols in place for grading the severity of side effects and initiating appropriate treatment.
If you experience any new or worsening symptoms after receiving Abecma, even if they occur weeks or months after the infusion, contact your healthcare provider. Some complications, such as prolonged cytopenias (low blood cell counts) and infections, can persist or develop well after the initial monitoring period.
How Should You Store Abecma?
Abecma must be stored frozen in the vapor phase of liquid nitrogen at or below −130°C. It should not be thawed until ready for use and must never be refrozen once thawed. Storage and handling are managed entirely by healthcare professionals at the treatment center.
As a patient, you will not be responsible for storing Abecma. The product is handled exclusively by trained healthcare professionals at certified treatment centers. However, understanding the storage requirements helps illustrate the complexity and precision involved in this therapy.
Abecma is stored and transported in the vapor phase of liquid nitrogen at temperatures of −130°C or below, contained within a specialized metal cassette. The product must not be thawed until the patient is ready to receive it, and thawing is carefully timed so that the infusion can begin promptly. Once thawed at approximately 37°C using an approved thawing device or water bath, the infusion must be completed within one hour of the start of thawing.
The infusion bag must not be used if it appears damaged, cracked, or leaking. Thawed Abecma must never be refrozen. If multiple infusion bags have been received for a single treatment, each bag is thawed separately and the timing is coordinated to ensure continuous administration.
Abecma should not be used past the expiration date printed on the cassette and infusion bag labels. Healthcare staff verify the integrity of each bag before administration and confirm that patient identification information on all labels matches the intended recipient.
What Does Abecma Contain?
Abecma contains idecabtagene vicleucel — the patient's own genetically modified T cells expressing an anti-BCMA chimeric antigen receptor. The formulation also contains CryoStor CS10, sodium chloride, sodium gluconate, sodium acetate trihydrate, potassium chloride, magnesium chloride, and water for injections.
The active ingredient in Abecma is idecabtagene vicleucel, consisting of autologous (patient-derived) T cells that have been genetically modified to express an anti-BCMA chimeric antigen receptor. Each infusion bag contains a batch-dependent concentration of these CAR-positive viable T cells. One or more bags may be required to deliver the target dose of 260 to 500 × 106 CAR-positive viable T cells.
Excipients (Inactive Ingredients)
The formulation contains the following inactive ingredients:
- CryoStor CS10 — cryopreservation medium containing dimethyl sulfoxide (DMSO)
- Sodium chloride
- Sodium gluconate
- Sodium acetate trihydrate
- Potassium chloride
- Magnesium chloride
- Water for injections
Important Composition Notes
This medicine contains genetically modified human blood cells. Patients and healthcare professionals should be aware of the following:
- Sodium content: Each dose contains up to 752 mg sodium (equivalent to 37.6% of the WHO-recommended maximum daily sodium intake for adults)
- Potassium content: Each dose contains up to 274 mg potassium, which should be considered for patients with reduced kidney function or those on a potassium-restricted diet
- DMSO content: If you have not previously been exposed to DMSO, you should be closely observed during the first minutes of the infusion for any adverse reactions
Appearance and Packaging
Abecma is a colorless cell dispersion for infusion, supplied in one or more infusion bags. Each bag is individually enclosed in a transparent plastic overwrap and packaged in a metal cassette for protection during frozen transport and storage. Each bag contains 10 to 100 mL of cell dispersion.
Frequently Asked Questions About Abecma
Abecma (idecabtagene vicleucel) is a CAR-T cell therapy used to treat adults with relapsed or refractory multiple myeloma. It works by collecting the patient's own white blood cells (T cells), genetically modifying them in a laboratory to express a chimeric antigen receptor (CAR) targeting BCMA on myeloma cells, and then infusing them back into the patient where they seek out and destroy cancer cells. This represents a fundamentally different approach compared to conventional chemotherapy, as it uses the body's own immune system to fight the cancer.
The most serious side effects include cytokine release syndrome (CRS), which causes fever, breathing difficulties, low blood pressure, and rapid heart rate; immune effector cell-associated neurotoxicity syndrome (ICANS), causing confusion, difficulty speaking, and reduced consciousness; severe infections due to low white blood cell counts; prolonged cytopenias; and rarely, secondary T-cell malignancies. Patients must remain near the treatment center for at least two weeks after infusion for close monitoring.
Abecma is given as a single intravenous infusion at a qualified treatment center. Before treatment, the patient undergoes leukapheresis to harvest T cells, which are sent to a manufacturing facility for genetic modification (taking approximately four weeks). Several days before the infusion, the patient receives lymphodepleting chemotherapy. On infusion day, the patient receives paracetamol and an antihistamine as premedication, followed by the Abecma infusion. The infusion must be completed within one hour of thawing the product.
Abecma is approved for adults with multiple myeloma who have received at least two prior therapies (in some regions three), including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and whose disease has progressed on or after the last treatment. Patients must be healthy enough to tolerate the treatment process, including lymphodepleting chemotherapy. Abecma is not approved for children or adolescents under 18 years of age.
No. You should not drive, operate machinery, or participate in activities requiring alertness for at least four weeks after receiving Abecma, or until your doctor confirms you have fully recovered. Abecma can cause drowsiness, confusion, and seizures. Depending on your individual recovery, your doctor may advise waiting longer before driving.
Abecma must be stored and transported frozen in the vapor phase of liquid nitrogen at or below −130°C. It should not be thawed until ready for use, and once thawed, the product must not be refrozen. Thawed Abecma must be infused within one hour. All storage and handling are managed by healthcare professionals at the treatment center — patients are not required to handle or store the product themselves.
References
- European Medicines Agency (EMA). Abecma (idecabtagene vicleucel) — Summary of Product Characteristics. Available at: ema.europa.eu/en/medicines/human/EPAR/abecma. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). ABECMA (idecabtagene vicleucel) — Prescribing Information. Approved March 2021, updated 2025.
- Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705-716. doi:10.1056/NEJMoa2024850
- Rodriguez-Otero P, Ailawadhi S, Engel A, et al. Idecabtagene vicleucel versus standard regimens in relapsed and refractory multiple myeloma (KarMMa-3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10406):1019-1032.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 3.2025.
- Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(3):309-322.
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.
- World Health Organization (WHO). International Classification of Diseases, 11th Revision (ICD-11). Multiple myeloma classification and coding.
About the Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialists in hematology-oncology, pharmacology, and clinical medicine. Our content follows the GRADE evidence framework and is based on peer-reviewed research, international clinical guidelines (EMA, FDA, NCCN, ESMO), and established medical standards.
Every article undergoes a rigorous multi-step review: initial research by medical writers, clinical accuracy verification by specialist physicians, editorial review for clarity and accessibility, and final approval by the Medical Review Board.
We prioritize Level 1A evidence from systematic reviews and randomized controlled trials. All medical claims are referenced to peer-reviewed sources. No commercial funding influences our content.
Last medically reviewed: | Published: | Read our editorial standards